Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 106 | 111 | 102 | 99 | 97 |
| Accounts payable and accrued liabilities | 1,455 | -1,423 | 489 | 1,132 | -3,126 |
| Other Working Capital | 1,535 | -2,555 | 908 | 2,280 | -5,515 |
| Other Operating Activity | -8,937 | -3,544 | -7,442 | -6,306 | 484 |
| Operating Cash Flow | $-5,841 | $-7,411 | $-5,943 | $-2,795 | $-8,060 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 8,300 | 7,750 | N/A | N/A | 0 |
| Common Stock Issued | 0 | -1 | 1 | 828 | 6,647 |
| Other Financing Activity | 0 | 1 | 2,499 | 1 | 158 |
| Financing Cash Flow | $8,300 | $7,750 | $2,500 | $829 | $6,805 |
| Exchange Rate Effect | N/A | N/A | N/A | 2 | 0 |
| Beginning Cash Position | 1,637 | 1,298 | 4,743 | 6,707 | 7,962 |
| End Cash Position | 4,096 | 1,637 | 1,298 | 4,743 | 6,707 |
| Net Cash Flow | $2,459 | $339 | $-3,443 | $-1,966 | $-1,255 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,841 | -7,411 | -5,943 | -2,795 | -8,060 |
| Free Cash Flow | -5,841 | -7,411 | -5,943 | -2,795 | -8,060 |